Table 1. Patient characteristics by aggressive and non-aggressive treatment (No of patients, %).
| All Patients (N=96,032) | Charlson 0 | Charlson 1 | Charlson 2 | Charlson 3+ | P-Value |
|---|---|---|---|---|---|
| Age at Diagnosis | <0.001 | ||||
| 66–69 | 19,903 (81%) | 3,357 (14%) | 789 (3%) | 411 (2%) | |
| 70–74 | 24,369 (78%) | 5,132 (16%) | 1,259 (4%) | 636 (2%) | |
| 76–80 | 17,629 (75%) | 4,157 (18%) | 1,224 (5%) | 652 (3%) | |
| >80 | 10,805 (33%) | 15,753 (47%) | 4,310 (13%) | 2,372 (7%) | |
| Race/Ethnicity | <0.001 | ||||
| White | 61,119 (78%) | 12,460 (16%) | 3,324 (4%) | 1,715 (2%) | |
| Black | 5,597 (68%) | 1,673 (20%) | 578 (7%) | 390 (5%) | |
| Hispanic | 3,124 (73%) | 792 (19%) | 221 (5%) | 144 (3%) | |
| Other | 3,629 (74%) | 911 (19%) | 219 (4%) | 136 (3%) | |
| Survival Outcomes | <0.001 | ||||
| Alive | 42,295 (83%) | 6,912 (14%) | 1,459 (3%) | 519 (1%) | |
| Other Causes | 27,857 (68%) | 8,345 (21%) | 2,725 (7%) | 1,763 (4%) | |
| Prostate Cancer | 3,117 (79%) | 579 (15%) | 158 (4%) | 103 (3%) | |
| Marital Status | <0.001 | ||||
| Married | 4,529 (74%) | 1,080 (18%) | 328 (5%) | 201 (3%) | |
| Unmarried | 68,940 (77%) | 14,756 (16%) | 4,014 (4%) | 2,184 (2%) | |
| Tumor Grade | <0.001 | ||||
| Well differentiated | 7,084 (75%) | 1,586 (17%) | 474 (5%) | 286 (3%) | |
| Moderately differentiated | 66,385 (77%) | 14,250 (16%) | 3,868 (4%) | 2,099 (2%) | |
| Tumor Stage | <0.001 | ||||
| T1 | 24,736 (75%) | 5,610 (17%) | 1,644 (5%) | 909 (3%) | |
| T2 | 31,596 (78%) | 6,496 (16%) | 1,676 (4%) | 965 (2%) | |
| T1/T2 | 17,137 (77%) | 3,730 (17%) | 1,022 (5%) | 511 (2%) | |
| Year of Diagnosis | <0.001 | ||||
| 1992–1997 | 24,972 (79%) | 4,788 (15%) | 1,266 (4%) | 655 (2%) | |
| 1998–2002 | 31,918 (76%) | 7,163 (17%) | 2,032 (5%) | 1,022 (2%) | |
| 2003–2007 | 16,579 (75%) | 3,865 (17%) | 1,044 (5%) | 708 (3%) | |
| SEER Region | <0.001 | ||||
| Connecticut | 6,915 (78%) | 1,359 (15%) | 382 (4%) | 188 (2%) | |
| Detroit | 9,406 (70%) | 2,757 (21%) | 764 (6%) | 511 (4%) | |
| Hawaii | 1,139 (77%) | 236 (16%) | 66 (4%) | 29 (2%) | |
| Iowa | 7,679 (80%) | 1,429 (15%) | 354 (4%) | 175 (2%) | |
| New Mexico | 3,232 (82%) | 538 (14%) | 130 (3%) | 56 (1%) | |
| Seattle | 5,950 (82%) | 936 (13%) | 241 (3%) | 110 (2%) | |
| Utah | 3,651 (83%) | 566 (13%) | 149 (3%) | 58 (1%) | |
| Atlanta | 2,872 (78%) | 571 (16%) | 163 (4%) | 69 (2%) | |
| Kentucky/Georgia* | 3,335 (66%) | 1,418 (28%) | 230 (5%) | 99 (2%) | |
| Louisiana | 2,682 (73%) | 629 (17%) | 196 (5%) | 143 (4%) | |
| New Jersey | 7,091 (72%) | 1,860 (19%) | 550 (6%) | 317 (3%) | |
| California | 19,517 (77%) | 4,113 (16%) | 1,117 (4%) | 630 (2%) |
*
Cells are combined due to SEER-Medicare rules regarding suppression of cell sizes less than 11.